Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial

Santo, Karla; Singleton, Anna; Rogers, Kris; Thiagalingam, Aravinda; Chalmers, John; Chow, Clara K; Redfern, Julie

doi:10.1136/heartjnl-2018-313479

Cited by 87 publications

(172 citation statements)

References 21 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…We considered 83 of these to be eligible and retrieved the full-text articles. Of these, nine studies reported outcome data eligible for meta-analysis 12 13 15 16 22–26. The screening process and reasons for exclusion are reported in figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…One study did not report the mean age but presented the percentage of participants whose age fell within a series of bandwidths 15. The percentage of participants in the intervention groups who were female ranged from 11%16 to 89%,22 and the mean percentage of female participants among the included studies was 45.2%.…”

Section: Resultsmentioning

confidence: 99%

“…Health problems of the target population varied between studies. Five studies sampled a patient population with cardiovascular disease,12 13 16 23 26 and each of the remaining four studies enrolled patient populations with different health problems: depression,22 Parkinson’s disease,24 psoriasis15 and multimorbidity 25…”

Section: Resultsmentioning

confidence: 99%

“…Where more than one app intervention was tested, data for the intervention considered most comparable with the other studies were extracted for meta-analysis. For example, one study investigated a ‘basic app’ (which provided a unidirectional once-daily reminder) as well as an ‘advanced app’ (which provided customisable and interactive features) versus usual care 16. The reviewers agreed that the advanced app was most comparable with the interventions of the other studies and so data pertaining to this intervention were extracted.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis

2020

View full text Add to dashboard Cite

ObjectivesTo estimate the efficacy of app-based interventions designed to support medication adherence and investigate which behaviour change techniques (BCTs) used by the apps are associated with efficacy.DesignSystematic review of randomised controlled trials (RCTs), with meta-analysis.SettingMedline/PubMed, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, Embase and Web of Science were searched from 1990 to November 2018 for RCTs conducted in any healthcare setting.ParticipantsStudies of participants of any age taking prescribed medication for any health condition and for any duration.InterventionAn app-based intervention delivered through a smartphone, tablet computer or personal digital assistant to help, support or advise about medication adherence.ComparatorOne of (1) usual care, (2) a control app which did not use any BCTs to improve medication adherence or (3) a non-app-based comparator.Primary and secondary outcome measuresThe primary outcome was the pooled effect size of changes in medication adherence. The secondary outcome was the association between BCTs used by the apps and the effect size.ResultsThe initial search identified 13 259 citations. After title and abstract screening, full-text articles of 83 studies were screened for eligibility. Nine RCTs with 1159 recruited participants were included. The mean age of participants was >50 years in all but one study. Health conditions of target populations included cardiovascular disease, depression, Parkinson’s disease, psoriasis and multimorbidity. The meta-analysis indicated that patients who use mobile apps to support them in taking medications are more likely to self-report adherence to medications (OR 2.120, 95% CI 1.635 to 2.747, n=988) than those in the comparator groups. Meta-regression of the BCTs did not reveal any significant associations with effect size.ConclusionsApp-based medication adherence interventions may have a positive effect on patient adherence. Larger scale studies are required to further evaluate this effect, including long-term sustainability, and intervention and participant characteristics that are associated with efficacy and app usage.Prospero registration numberPROSPERO Protocol Registration Number: CRD42017080150.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis

2020

View full text Add to dashboard Cite

show abstract

“…Despite the abundance of cancer-related apps, few provide evidence-based information (Pandey, Hasan, Dubey, & Sarangi, 2013;Vollmer Dahlke, Fair, Hong, Beaudoin, Pulczinski, & Ory, 2015) and some apps provide misinformation that may be harmful to consumers (Mobasheri, Johnston, King, Leff, Thiruchelvam, & Darzi, 2014). Although preliminary results of tested apps are promising, most apps focused on improving one specific health outcome and/or had short-term follow-up (1-6 months) (McCarroll et al, 2015;Santo et al, 2018). Further research into app safety, the effect of multi-domain apps (psychosocial, medication adherence, physical activity, nutrition) and long-term app-use on patient outcomes and attrition (Eysenbach, 2005) is needed.…”

Section: Smartphone Applications (Apps)mentioning

confidence: 99%

The Potential for mHealth Interventions to Support Women with Breast Cancer after Active Treatment

Singleton

Raeside

Partridge

et al. 2019

RHS

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer among women worldwide. Chances of living one-year after diagnosis are high (~98%), and health self-management is essential to reduce risks of recurrence. Mobile health (mHealth) has emerged as a wide-reaching and cost-effective way of providing health information and support. Therefore, we conducted a narrative review of the currently available mHealth literature and synthesised the literature according to the impacts of mHealth interventions on patient outcomes, the potential mechanism for behaviour change and innovative approaches to developing future mHealth interventions. Results found a small amount of evidence for the value of mHealth interventions (text message programs, smartphone applications and activity trackers) for supporting women after breast cancer treatment. However, accessibility, cost and gender inequities may pose barriers to implementation. Developing consumer-led mHealth interventions based on lived-experiences will be essential to improving user outcomes. In conclusion, mHealth interventions are widely available and have the potential to support women after breast cancer treatment and further robust research will determine effectiveness in specific subgroups and populations.

show abstract

Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease

Redfern,

Tu,

Hyun

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for almost 18 million deaths annually. People with CVDs have a five times greater chance of suffering a recurrent cardiovascular event than people without known CVDs. Although drug interventions have been shown to be cost‐effective in reducing the risk of recurrent cardiovascular events, adherence to medication remains suboptimal. As a scalable and cost‐effective approach, mobile phone text messaging presents an opportunity to convey health information, deliver electronic reminders, and encourage behaviour change. However, it is uncertain whether text messaging can improve medication adherence and clinical outcomes. This is an update of a Cochrane review published in 2017. Objectives To evaluate the benefits and harms of mobile phone text messaging for improving medication adherence in people with CVDs compared to usual care. Search methods We searched CENTRAL, MEDLINE, Embase, four other databases, and two trial registers. We also checked the reference lists of all primary included studies and relevant systematic reviews and meta‐analyses. The date of the latest search was 30 August 2023. Selection criteria We included randomised controlled trials (RCTs) with participants with established arterial occlusive events. We included trials investigating interventions using short message service (SMS) or multimedia messaging service (MMS) with the aim of improving adherence to medication for the secondary prevention of cardiovascular events. The comparator was usual care. We excluded cluster‐RCTs and quasi‐RCTs. Data collection and analysis We used standard Cochrane methods. Our primary outcomes were medication adherence, fatal cardiovascular events, non‐fatal cardiovascular events, and combined CVD event. Secondary outcomes were low‐density lipoprotein cholesterol for the effect of statins, blood pressure for antihypertensive drugs, heart rate for the effect of beta‐blockers, urinary 11‐dehydrothromboxane B2 for the antiplatelet effects of aspirin, adverse effects, and patient‐reported experience. We used GRADE to assess the certainty of the evidence for each outcome. Main results We included 18 RCTs involving a total of 8136 participants with CVDs. We identified 11 new studies in the review update and seven studies in the previous version of the review. Participants had various CVDs including acute coronary syndrome, coronary heart disease, stroke, myocardial infarction, and angina. All studies were conducted in middle‐ and high‐income countries, with no studies conducted in low‐income countries. The mean age of participants was 53 to 64 years. Participants were recruited from hospitals or cardiac rehabilitation facilities. Follow‐up ranged from one to 12 months. There was variation in the characteristics of text messages amongst studies (e.g. del...

show abstract

Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial

Abstract: ACTRN12616000661471; Results.

Cited by 87 publications

References 21 publications

Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis

Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis

The Potential for mHealth Interventions to Support Women with Breast Cancer after Active Treatment

Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease

Contact Info

Product

Resources

About